We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Surrogate Marker Described for Pancreatic Neuroendocrine Tumors

By LabMedica International staff writers
Posted on 19 May 2022
Print article
Image: Photomicrograph of histology of pancreatic neuroendocrine tumor (Photo courtesy of Nephron)
Image: Photomicrograph of histology of pancreatic neuroendocrine tumor (Photo courtesy of Nephron)

Tumors of the endocrine pancreas are a collection of tumor cell types collectively referred to as PanNETs. These tumors originate in islet cells. Although they may be similar or identical in histologic appearance to carcinoid tumors of the gastrointestinal tract, differences in their underlying biology and likely differences in response to therapeutic agents suggest that they should be treated and investigated as a distinct entity.

Pancreatic neuroendocrine tumor (PanNET) is the second most common solid neoplasm of the pancreas, accounting for 3% to 4% of all pancreas neoplasms. The incidence of this tumor has increased owing to advances in various imaging techniques and increasing awareness. Surgical resection is the main treatment option for localized PanNETs, both functioning and nonfunctioning, without distant metastasis.

Pathologists at the University of Ulsan College of Medicine (Seoul, Republic of Korea) assessed the significance of tumor border, a well-known prognostic indicator in other cancers, in the PanNETs. They evaluated the macroscopic growth pattern (expansile [Exp] versus infiltrative [Inf]) and the microscopic tumor border (pushing [Pus] versus Inf) of 203 surgically resected PanNETs and compared them with other clinicopathologic factors.

Growth pattern and tumor border were evaluated at the junctions between tumor and normal pancreatic parenchyma or between tumor and other adjacent organs by both gross and microscopic examination. First, macroscopic growth pattern was evaluated in PanNET cases with available gross images of the cut surface of the PanNETs and was classified as expansile or infiltrative pattern. Expansile growth pattern was defined when the tumor had well-delineated margin from adjacent parenchyma. Microscopic tumor border was categorized as pushing or infiltrative. When the tumor boundary was well circumscribed under microscopic examination, this was referred to as a pushing border. Tissue microarray (TMA) was constructed from archived, formalin-fixed, paraffin-embedded tissue blocks with a manual tissue microarrayer (UNITMA Co Ltd, Seoul, Korea).

The scientists reported that based on macroscopic growth pattern, 83 cases had Exp patterns whereas 84 had Inf patterns. According to microscopic tumor border, 122 PanNETs had Pus borders whereas 81 had Inf borders. Combining macroscopic growth pattern and microscopic tumor border, 65 PanNETs had Exp/Pus, 34 had Inf/Pus, 18 had Exp/Inf, and 50 had Inf/Inf status. PanNETs with Inf/Inf status were associated with higher tumor grade, pT classification, and American Joint Committee on Cancer stage grouping; lymph node metastasis; and lymphovascular and perineural invasion.. Patients with PanNET having Inf/Inf status had significantly shorter overall survival (OS) and recurrence-free survival (RFS). Further, using multivariate analysis, Inf/Inf status was identified as an independent poor prognostic factor of OS and RFS.

The authors concluded that the combined Inf/Inf status was observed in approximately 25% of PanNETs and was associated with aggressive biological behavior and short OS and RFS. Therefore, assessing combined macroscopic growth pattern and microscopic tumor border can provide additional information regarding survival and recurrence in PanNET patients. The study was published on May 9, 2022 in the journal Archives of Pathology and Laboratory Medicine.

Related Links:
University of Ulsan College of Medicine 

Gold Supplier
SARS-CoV-2 Assay
Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
Silver Supplier
Urea Breath Test
13C-Urea Breath Test
Cancer Rapid Diagnostic Test
Xpert Breast Cancer STRAT4

Print article


Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.